Imagine a world where a stroke victim in a remote village could receive life-saving surgery from a specialist thousands of miles away. Sounds like science fiction, right? But that future is closer than you think. A groundbreaking collaboration between surgeons in Dundee, Scotland, and the US has achieved a world-first: performing stroke surgery using a robot. This isn't just a technological marvel; it's a potential lifeline for millions who lack access to specialized stroke care.
BBC News reveals that Professor Iris Grunwald of the University of Dundee led the charge, conducting the first remote thrombectomy—a procedure to remove blood clots after a stroke—on a donated human cadaver. Here’s the twist: while Prof. Grunwald was at Ninewells Hospital in Dundee, the cadaver was across the city at the university. And this is the part most people miss: just hours later, neurosurgeon Ricardo Hanel in Florida replicated the feat, performing the first transatlantic surgery on a human body over 4,000 miles away in Dundee.
The team hails this as a potential “game changer” if approved for patient use. Why? Because stroke treatment is a race against time. Delays in accessing specialists can drastically reduce recovery chances. Prof. Grunwald aptly described it as “witnessing the first glimpse of the future,” turning what was once considered science fiction into reality.
The University of Dundee, already a global training hub for interventional stroke treatment, is uniquely positioned for such innovation. It’s the only UK institution where doctors can practice on cadavers with human blood circulated in vessels, simulating live treatments. Prof. Grunwald emphasized, “This was the first time we could perform the entire mechanical thrombectomy procedure on a real human body, proving every step is possible.”
Juliet Bouverie, CEO of the Stroke Association, called the transatlantic procedure “a remarkable innovation.” She highlighted a stark reality: people in remote and rural areas are often denied access to thrombectomy. “Robotics like this could rebalance the inequity in stroke treatment across the UK,” she added.
Here’s how it works: during an ischemic stroke, a blood clot blocks an artery, cutting off blood and oxygen to the brain. Brain cells die rapidly, making every minute critical. The gold standard treatment is a thrombectomy, where specialists use catheters and wires to remove the clot. But here’s where it gets controversial: what if the patient is hours away from the nearest specialist?
Prof. Grunwald’s experiment demonstrated that a robot can be connected to the same catheters and wires a surgeon would use. A local medic attaches the wires to the patient, while the remote surgeon controls the robot in real time, performing the thrombectomy as if they were in the same room. The surgeon could even operate from home, using the Sentante machine developed by a Lithuanian firm.
Tech giants Nvidia and Ericsson ensured seamless connectivity, with Dr. Hanel marveling at the 120-millisecond lag—“a blink of an eye”—between the US and Scotland. Prof. Grunwald, who trained in just 20 minutes, noted the technology’s potential to overcome two critical challenges: the global shortage of thrombectomy-trained doctors and the geographical barriers to treatment.
In Scotland, only Dundee, Glasgow, and Edinburgh offer thrombectomy. For the rest, travel is unavoidable. “Every six-minute delay reduces the chance of a good outcome by 1%,” Prof. Grunwald explained. “This technology could save those precious minutes, regardless of where you live.”
Public Health Scotland reported 9,625 ischemic strokes last year, yet only 2.2% of patients received thrombectomy. Across the UK, the figure is just 3.9%. Sentante CEO Edvardas Satkauskas summed it up: “Sometimes, the future is way closer than we think.”
But here’s the question: Will this technology truly democratize stroke care, or will it remain out of reach for many? Could it exacerbate existing inequalities if only wealthy nations adopt it? We’d love to hear your thoughts in the comments. The future of stroke treatment is here—but who will it serve?
